PATEL DINESH V PH D

CIK 00011204771 companyNEWARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001120477

Recent Transactions

50 trades

Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-27$21.58/sh+4,068→ 578,573 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-27$83.19/sh−4,068→ 574,505 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-27−4,068→ 300,000 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-26$84.05/sh−14,205→ 574,505 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-26$84.00/sh−10,685→ 574,505 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-26$21.58/sh+14,205→ 588,710 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-26−10,685→ 0 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-26$4.21/sh+10,685→ 585,190 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-26−14,205→ 304,068 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-23$84.59/sh−19,315→ 574,505 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-23$4.21/sh+19,315→ 593,820 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-23−6,000→ 574,505 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-23−19,315→ 10,685 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-20$82.48/sh−34,438→ 580,505 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-02+120,200→ 120,200 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-02+95,400→ 614,943 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-11-21−440→ 519,543 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-09-16−620→ 519,983 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-07-25$54.78/sh−10,415→ 520,603 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-07-23$54.79/sh−17,520→ 531,018 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-07-22$55.05/sh−22,065→ 548,538 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-07-21+25,000→ 583,462 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-07-21$54.86/sh−12,859→ 570,603 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-07-16−5,000→ 558,462 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-06-16−685→ 562,905 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-06-13−670→ 563,590 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-05$4.21/sh+24,000→ 564,260 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-03-05−24,000→ 30,000 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-02-19$38.18/sh−5,359→ 540,260 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-15−12,636→ 545,619 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-02+149,800→ 558,255 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-01-02+181,472→ 181,472 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-26$46.25/sh−21,480→ 408,455 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-25−7,000→ 428,208 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-11-25−1,727→ 318,273 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-25$46.96/sh−78,520→ 435,208 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-25$21.58/sh+1,727→ 429,935 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-11-19−1,000→ 513,415 total
Gift
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-06-13−1,000→ 514,415 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-06-07$35.19/sh−35,000→ 515,415 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-04-01$28.31/sh−25,000→ 549,590 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-03-01$31.62/sh−30,000→ 574,590 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-02-26$29.53/sh−10,915→ 604,590 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-02-15$28.23/sh−3,717→ 615,505 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-01-02+84,875→ 619,222 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-01-02+315,250→ 315,250 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-12-13$20.08/sh−75,000→ 534,347 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2023-10-18−6,000→ 54,000 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-10-18$4.21/sh+6,000→ 609,347 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-05-31$26.07/sh−12,165→ 602,946 total

Companies

Protagonist Therapeutics, Inc
Director, President and CEO
$PTGX

Recent Filings

Address

C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560-1160

View on SEC.gov